Aflac (NYSE:AFL) is scheduled to announce its second-quarter earnings for 2025 on August 5. The announcement will take place after the market closes, and analysts are anticipating earnings of $1.73 per share alongside revenue projections of $4.30 billion for the quarter.
On Monday, Aflac’s stock opened at $98.10, reflecting a decrease of 1.3%. Currently, the company holds a market capitalization of $53.04 billion and has a price-to-earnings ratio of 15.33. The stock has exhibited a beta of 0.83, indicating lower volatility compared to the overall market. Aflac’s 50-day simple moving average stands at $102.58, while the 200-day average is at $105.05. The stock has fluctuated between a 52-week low of $95.97 and a high of $115.50.
Recent Insider Transactions and Analyst Ratings
In related news, recent insider trading may have implications for investor sentiment. On May 8, Director Joseph L. Moskowitz sold 1,000 shares at an average price of $106.79, resulting in a total of $106,790. Following this sale, Moskowitz retained 26,096 shares, valued at approximately $2.79 million, marking a 3.69% decrease in his holdings. This transaction has been officially reported to the Securities and Exchange Commission.
Another notable transaction occurred on May 15, when Director Arthur Reginald Collins sold 2,750 shares for a total of $290,675, which represented a 29.01% decrease in his ownership. Following the sale, Collins now owns 6,728 shares valued at approximately $711,150. In total, insiders have sold 40,750 shares worth $4.3 million in the last quarter, with corporate insiders holding 0.80% of the company’s stock.
As analysts prepare for the earnings report, several brokerages have issued updates regarding Aflac’s stock. Barclays has set a price target of $98.00 with an “underweight” rating. Meanwhile, Wall Street Zen recently downgraded Aflac from a “hold” to a “sell” rating. Conversely, JPMorgan Chase & Co. raised its price target from $96.00 to $100.00 while maintaining a “neutral” rating.
Aflac’s Operations and Market Position
Aflac operates primarily through its subsidiaries, providing supplemental health and life insurance products. The company is divided into two main segments: Aflac Japan and Aflac U.S. The Japan segment offers various insurance products, including cancer, medical, and life insurance.
Currently, Aflac holds an average rating of “Hold” from analysts, with a consensus target price of $108.15. With the upcoming earnings announcement, investors and analysts alike will closely monitor the firm’s performance and future outlook.
